A61K 47/6841
The antibody targeting a rna virus
Official title: {the antibody targeting a RNA virus}
A61K47/6841 (The antibody targeting a rna virus) appears on 86 US grants and 131 published applications in this corpus.
Search patents in A61K- Granted patents
- 86
- Published applications
- 131
- Assignees
- 67
- Inventors
- 257
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 3 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 4 |
| 2011 | 2 | 4 |
| 2012 | 2 | 3 |
| 2013 | 2 | 4 |
| 2014 | 9 | 9 |
| 2015 | 9 | 8 |
| 2016 | 6 | 13 |
| 2017 | 7 | 8 |
| 2018 | 3 | 7 |
| 2019 | 6 | 6 |
| 2020 | 8 | 11 |
| 2021 | 11 | 7 |
| 2022 | 3 | 6 |
| 2023 | 3 | 7 |
| 2024 | 4 | 12 |
| 2025 | 4 | 6 |
| 2026 | 3 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Lassa virus-specific nanobodies and methods of their use29 Sep 2026US 12,747,284 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces10 Mar 2026US 12,570,763 B2The Board of Trustees of the Leland Stanford Junior University
- Protein-antiviral compound conjugates3 Mar 2026US 12,564,640 B2Regeneron Pharmaceuticals, Inc.
- Antibody drug conjugates comprising sting agonists14 Oct 2025US 12,440,576 B2Mersana Therapeutics, Inc.
- Anti-dengue vaccines and antibodies16 Sep 2025US 12,415,836 B2Oxford University Innovation Limited
- Antibodies that bind to multiple sarbecoviruses17 Sep 2026US 2026/0274928 A1Vir Biotechnology, Inc.
- Nanobody for norovirus10 Sep 2026US 2026/0265349 A1Griffith University
- Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof10 Sep 2026US 2026/0266820 A1Icahn School of Medicine at Mount Sinai
- Protein-antiviral compound conjugates13 Aug 2026US 2026/0232822 A1Regeneron Pharmaceuticals, Inc.
- Anti-dengue vaccines and antibodies26 Feb 2026US 2026/0055145 A1Oxford University Innovation Limited
Most cited
By later US patents
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012
- Camptothecin-binding moiety conjugates48US 8,877,901 B2Immunomedics, Inc. · 2014